Use of quality checks and processes across digital histopathology: an initial survey from the Bigpicture consortium.

Hayley Pye¹, David S Brettle², Caitríona Lyons³, Fauve Versaevel⁴, Erio Barale-Thomas⁴, Kurt Zatloukal⁵, Darren Treanor^2,6,

¹National Pathology Imaging Co-operative, Leeds Teaching Hospitals NHS Trust, Leeds, UK hayley.pye@nhs.net.

²National Pathology Imaging Co-operative, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

³Deciphex Ltd, Dublin, Ireland.

⁴A Johnson & Johnson Company, Janssen Pharmaceutica NV, Beerse, Belgium.

⁵Institute of Pathology, Medical University of Graz, Graz, Austria.

⁶Department of Clinical and Experimental Medicine, Linkopings Universitet, Linköping, Sweden.

PubMed PMC DOI PDF

Abstract

AIMS: In the end-to-end digital pathology workflow, variability can be introduced at each step, resulting in differences in the final image dataset. The effectiveness of quality control processes at each step of the workflow will impact the extent and relevance of this variability. METHODS: To assess the maturity of whole slide imaging (WSI) quality processes for the whole digital pathology workf…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.